The Patient aged 18 years and overand Non-
Conditions
Interventions
The group receiving the drug Stimulated standard-
dose white blood cells (5 μg / kg) and CBC blood test prior to chemotherapy,
and CBC prescribed date on chemotherapy prescription such as CBC on 5th,
Day 14,
Day 17,
Day 20 and daily blood tests until neutrophil recovery
,
with additional blood tests in addition to routine care on Day 18,
Day 19,
as investigators reviewed the treatment history of leukemia patients. Acute myeloid leukemia in the sedative phase receiving chemotherapy with cytarabine. In the past at Siriraj Hospital,
incidence of neutrophil recovery was more frequent during this time (filgrastim was given on the 6th day after chemotherapy was administered following the current chemotherapy regimen at Siriraj Hospi
dose white blood cells (10 μg / kg) and CBC blood test prior to chemotherapy,
Sponsors
Siriraj Hospital Mahidol University
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Non-M3 acute myeloid leukemia patients in the sedative stage who received cytarabine consolidation therapy 2. CBC had absolute neutrophil count> 1,000 / μL and platelet count ≥ 100,000 / μL and blast cell <5% in bone. marrow 3. Patient aged 18 years and over.
Exclusion criteria
Exclusion criteria: 1. Patients with other types of cancer or an infection that has spread into the bone marrow 2. Patients receiving immunosuppressants who also treat other diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of leukocytes in patients acute myeloid leukemia receiving filgrastim 2 years Number in leukocytes patients per normal population | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduce infection and side effects 2 yaers Number in infection and side effects patients in normal | — |
Countries
Thailand
Contacts
Public ContactWeerapat Owattanapanich
Division of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol Unive
Outcome results
None listed